跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR T-cell therapy (hematological cancers)
首页
药物
CAR T-cell therapy (hematological cancers)
CAR T-cell therapy (hematological cancers)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
Compositions and methods for chimeric antigen receptors specific for B-cell receptors
申请人: UNIV PENNSYLVANIA
优先权: 2021
CN
METHOD TO GENERATE IMPROVING CAR-T CELLS
申请人: INST NAT SANTE RECH MED
优先权: 2022
EP
US
WO
3 件公开
mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
申请人: SWARTZ ROGER B
优先权: 2021
US
药物
反馈
